Pharvaris Provides Business Update and Expands Development Program for DeucrictibantGlobeNewsWire • 09/05/24
Pharvaris Presents Deucrictibant Long-Term Extension Data for Both the Prophylactic and On-Demand Treatment of HAE at the Bradykinin Symposium 2024GlobeNewsWire • 09/05/24
Deucrictibant Clinical, Real-World, Nonclinical, and Discovery Data to be Presented at the Bradykinin SymposiumGlobeNewsWire • 08/28/24
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 08/14/24
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent CongressesGlobeNewsWire • 06/04/24
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/08/24
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 04/10/24
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 ConferenceGlobeNewsWire • 04/04/24
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE CongressesGlobeNewsWire • 03/18/24
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual MeetingGlobeNewsWire • 02/22/24
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE AttacksGlobeNewsWire • 01/22/24
Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023GlobeNewsWire • 12/08/23